Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Mechanisms of the IL-33/ST2 Signaling Axis in Regulating Bone Metabolism.

Biomolecules·2026
Same author

Repeated-dose toxicity and immunogenicity evaluation of norovirus P particle-based rotavirus vaccine in juvenile cynomolgus monkeys.

Frontiers in immunology·2026
Same author

Rapid adaptation and enrichment of salt-tolerant anammox via dosing of chemical enhancers in packed-bed biofilm reactor.

Water research·2026
Same author

Diagnostic Value of Spectral CT-Derived Extracellular Volume Fraction in the Early Detection of Sigmoid Colon Metastasis from Bladder Cancer: A Case Report.

Surgical case reports·2026
Same author

Fat Grafting via the Supraorbital Approach for Upper-Eyelid Depression Correction: A Retrospective Study.

Aesthetic plastic surgery·2026
Same author

Integrative Multi-Omics Analysis Prioritizes Candidate Therapeutic Targets for Primary Open-Angle Glaucoma.

International journal of molecular sciences·2026
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
Same journal

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026
查看所有相关文章

相关实验视频

Updated: Jan 15, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

631

一个周期后的深度dFLC降低预测AL氨基粉症患者的优异结果.

Yang Liu1, Jingyi Bi1, Xuelin Dou1

  • 1Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Center of Hematologic Disease, Beijing, China.

Leukemia & lymphoma
|October 15, 2025
PubMed
概括
此摘要是机器生成的。

参与和不参与的自由光链 (dFLC) 之间的差异的早期减少预测了用daratumumab-bortezomib. 一个循环后87%以上的减少表明最佳反应和完全血液和器官反应的更高机会.

关键词:
在AL氨基粉症症.参与和不参与的自由轻链之间的差异.早期反应的早期反应

更多相关视频

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

14.0K
Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
08:25

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

4.0K

相关实验视频

Last Updated: Jan 15, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

631
Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

14.0K
Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
08:25

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

4.0K

科学领域:

  • 血液学 血液学 血液学
  • 在瘤学瘤学.
  • 临床医学 临床医学

背景情况:

  • 粉样粉症是一种血细胞疾病,其特征是错误折叠的免疫球蛋白轻链的沉积.
  • 对治疗反应的早期评估对于管理AL氨基粉症和改善患者的治疗结果至关重要.

研究的目的:

  • 调查参与和不参与的自由光链 (dFLC) 之间的差异早期减少与AL氨基粉症患者的临床结果之间的关系.
  • 确定一个治疗周期后dFLC减少的预测值.

主要方法:

  • 一项多中心研究包括86名患有AL氨基粉症的患者 (基线dFLC≥50mg/L) 接受前线daratumumab-bortezomib.
  • 用接收器操作特征 (ROC) 分析来确定dFLC减少的预测值,以确定完整的血液反应 (CHR).
  • 根据dFLC减少 (>87%) 或一个周期后非常好的部分反应,患者被分为最佳响应者 (O-HR) 或亚最佳响应者 (S-HR).

主要成果:

  • 在一个周期后,dFLC的87%降低被确定为CHR的预测 (AUC = 0.82).
  • 最佳响应者 (O-HR) 的CHR (90.5%对43.5%),心脏响应 (68.9%对36.8%) 和脏响应 (76.6%对50.0%) 的比率明显更高,相比于低于最佳响应者 (S-HR).

结论:

  • 在达拉图穆马布-博特佐米布治疗一轮后,dFLC的严重下降是完全血液反应和AL氨基粉症中有利的器官反应的强有力的预测因素.
  • 这些发现支持使用早期的dFLC动力学来指导治疗决策,并可能改变AL氨基粉症的治疗方法.